BACKGROUND: Vildagliptin is a dipeptidyl peptidase IV inhibitor (DPP4i). Its 
efficacy and safety of DPP4i in Chilean real life type 2 diabetic (T2D) patients 
is not well known.
AIM: To assess the safety profile and effectiveness of 12 weeks of treatment 
with Vildagliptin for glycemic control in T2D Chilean patients with a poor 
glycemic control.
PATIENTS AND METHODS: Retrospective assessment of the effects of Vildagliptin 
treatment during 12 weeks in 103 T2D patients aged 29 to 92 years (47% males). 
The main outcomes were changes in glycosylated hemoglobin and the occurrence of 
adverse effects.
RESULTS: After 12 weeks of Vildagliptin use, glycosylated hemoglobin decreased 
from 8.3 ± 1.4 to 7.2 ± 1.1% (p < 0.01). Fasting plasma glucose and the number 
of hypoglycemic events also decreased significantly. No significant weight 
change was observed. The treatment had good compliance, tolerance and patient 
satisfaction.
CONCLUSIONS: Vildagliptin treatment reduced glycosylated hemoglobin by 1.1% and 
was well tolerated in this group of diabetic patients.